Tags

Type your tag names separated by a space and hit enter

Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.
J Clin Psychiatry. 2001; 62 Suppl 2:17-21.JC

Abstract

Behavioral agitation and prominent positive psychotic symptoms often characterize the acute presentation of schizophrenia. The clinical treatment goal is a rapid control of these symptoms. The relative efficacy of olanzapine, a novel antipsychotic drug, was compared with that of the conventional antipsychotic drug haloperidol. A post hoc analysis conducted on a large multicenter, double-blind, 6-week study of acute-phase patients with DSM-III-R schizophrenia or schizophreniform or schizoaffective disorders treated with olanzapine (5-20 mg/day) or haloperidol (5-20 mg/day) assessed the treatment effects on agitation (Brief Psychiatric Rating Scale [BPRS] agitation score) and positive symptoms (BPRS positive symptom score). Overall, olanzapine-treated patients experienced significantly greater improvement in behavioral agitation than did haloperidol-treated patients (last observation carried forward [LOCF]; p < .0002). Both groups showed similar reductions in agitation scores during the first 3 weeks of therapy; olanzapine was associated with significantly greater improvements at weeks 4, 5, and 6 (observed cases [OC]). Similarly, patients with predominantly positive psychotic symptoms experienced significantly greater improvement in BPRS positive symptom scores with olanzapine compared with haloperidol (LOCF; p = .013). In olanzapine-treated patients, improvement in BPRS agitation and positive symptom scores was significantly greater at weeks 4, 5, and 6 (agitation scores, p < or = .01; positive symptom scores, p < .05) (OC). These data suggest that olanzapine may be considered a first-line treatment for the patient in an acute episode of schizophrenia.

Authors+Show Affiliations

Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Ind 46285, USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11232746

Citation

Kinon, B J., et al. "Effective Resolution With Olanzapine of Acute Presentation of Behavioral Agitation and Positive Psychotic Symptoms in Schizophrenia." The Journal of Clinical Psychiatry, vol. 62 Suppl 2, 2001, pp. 17-21.
Kinon BJ, Roychowdhury SM, Milton DR, et al. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. J Clin Psychiatry. 2001;62 Suppl 2:17-21.
Kinon, B. J., Roychowdhury, S. M., Milton, D. R., & Hill, A. L. (2001). Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. The Journal of Clinical Psychiatry, 62 Suppl 2, 17-21.
Kinon BJ, et al. Effective Resolution With Olanzapine of Acute Presentation of Behavioral Agitation and Positive Psychotic Symptoms in Schizophrenia. J Clin Psychiatry. 2001;62 Suppl 2:17-21. PubMed PMID: 11232746.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. AU - Kinon,B J, AU - Roychowdhury,S M, AU - Milton,D R, AU - Hill,A L, PY - 2001/3/10/pubmed PY - 2001/3/17/medline PY - 2001/3/10/entrez SP - 17 EP - 21 JF - The Journal of clinical psychiatry JO - J Clin Psychiatry VL - 62 Suppl 2 N2 - Behavioral agitation and prominent positive psychotic symptoms often characterize the acute presentation of schizophrenia. The clinical treatment goal is a rapid control of these symptoms. The relative efficacy of olanzapine, a novel antipsychotic drug, was compared with that of the conventional antipsychotic drug haloperidol. A post hoc analysis conducted on a large multicenter, double-blind, 6-week study of acute-phase patients with DSM-III-R schizophrenia or schizophreniform or schizoaffective disorders treated with olanzapine (5-20 mg/day) or haloperidol (5-20 mg/day) assessed the treatment effects on agitation (Brief Psychiatric Rating Scale [BPRS] agitation score) and positive symptoms (BPRS positive symptom score). Overall, olanzapine-treated patients experienced significantly greater improvement in behavioral agitation than did haloperidol-treated patients (last observation carried forward [LOCF]; p < .0002). Both groups showed similar reductions in agitation scores during the first 3 weeks of therapy; olanzapine was associated with significantly greater improvements at weeks 4, 5, and 6 (observed cases [OC]). Similarly, patients with predominantly positive psychotic symptoms experienced significantly greater improvement in BPRS positive symptom scores with olanzapine compared with haloperidol (LOCF; p = .013). In olanzapine-treated patients, improvement in BPRS agitation and positive symptom scores was significantly greater at weeks 4, 5, and 6 (agitation scores, p < or = .01; positive symptom scores, p < .05) (OC). These data suggest that olanzapine may be considered a first-line treatment for the patient in an acute episode of schizophrenia. SN - 0160-6689 UR - https://www.unboundmedicine.com/medline/citation/11232746/Effective_resolution_with_olanzapine_of_acute_presentation_of_behavioral_agitation_and_positive_psychotic_symptoms_in_schizophrenia_ L2 - http://www.psychiatrist.com/jcp/article/pages/2001/v62s02/v62s0204.aspx DB - PRIME DP - Unbound Medicine ER -